## ADDITIONAL INFORMATION REGARDING ELECTRONIC CLINICAL QUALITY MEASURES (eCQMs) FOR CMS REPORTING PROGRAMS FOR ELIGIBLE PROFESSIONALS AND ELIGIBLE CLINICIANS<sup>1</sup>

The table below entitled "Electronic Clinical Quality Measures for Eligible Professionals and Eligible Clinicians" contains additional up-to-date information for electronic clinical quality measures (eCQMS) for the Centers for Medicare & Medicaid Services (CMS) quality reporting programs. Subsequent updates will be provided in a new version of this table, and CMS will maintain and publish an archive of each update.

Please note the titles and descriptions for the eCQMs included in this table were updated by the measure stewards and therefore may not match the information provided on the National Quality Forum (NQF) website. Measures that do not have an NQF number are not currently endorsed.

In an effort to align the eCQMs used in CMS quality reporting programs with the goals of CMS and the Department of Health and Human Services, the National Quality Strategy (NQS), and recommendations from the Health Information Technology Policy Committee, each eCQM has been assessed against six domains based on the six priorities of the NQS. This revised table removes the previous Meaningful Use domains and now aligns with the domains listed in the Merit-based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Quality Payment Program. The following domains have been integrated into this table:

- Person and Caregiver-Centered Experience and Outcomes
- Patient Safety
- Communication and Care Coordination
- Community/Population Health
- Efficiency and Cost Reduction
- Effective Clinical Care

<sup>&</sup>lt;sup>1</sup> Eligible Clinicians applies to MIPS Eligible Clinicians and similar participants of other CMS programs using eCQMs for quality reporting such as Alternative Payment Model participants.

## **ELECTRONIC CLINICAL QUALITY MEASURES FOR ELIGIBLE PROFESSIONALS AND ELIGIBLE CLINICIANS**

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description   | Numerator Statement   | Denominator Statement  | Measure<br>Steward                                | PQRS# |
|-----------------------|-------------------|--|---|---|--|---|-------|
| CMS146v5              | Not<br>Applicable | Appropriate Testing for<br>Children with<br>Pharyngitis<br>Domain: Efficiency and<br>Cost Reduction      | Percentage of children 3-<br>18 years of age who were<br>diagnosed with<br>pharyngitis, ordered an<br>antibiotic and received a<br>group A streptococcus<br>(strep) test for the episode  | Children with a group<br>A streptococcus test in<br>the 7-day period from<br>3 days prior through 3<br>days after the<br>diagnosis of<br>pharyngitis  | Children 3-18 years of age who had an outpatient or emergency department (ED) visit with a diagnosis of pharyngitis during the measurement period and an antibiotic ordered on or three days after the visit | National<br>Committee<br>for Quality<br>Assurance | 066   |
| CMS137v5              | 0004              | Initiation and Engagement of Alcohol and Other Drug Dependence Treatment Domain: Effective Clinical Care | Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.  Percentage of patients who initiated treatment within 14 days of the diagnosis.  Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit. | Numerator 1: Patients who initiated treatment within 14 days of the diagnosis  Numerator 2: Patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit | Patients age 13 years of age and older who were diagnosed with a new episode of alcohol or drug dependency during a visit in the first 11 months of the measurement period                                   | National<br>Committee<br>for Quality<br>Assurance | 305   |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain   | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward                                | PQRS#                |
|-----------------------|------|---|--|---|---|---|----------------------|
| CMS165v5              | 0018 | Controlling High Blood<br>Pressure<br>Domain: Effective<br>Clinical Care    | Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period   | Patients whose blood pressure at the most recent visit is adequately controlled (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg) during the measurement period                                     | Patients 18-85 years of age who had a diagnosis of essential hypertension within the first six months of the measurement period or any time prior to the measurement period | National<br>Committee<br>for Quality<br>Assurance | 236<br>GPRO<br>HTN-2 |
| CMS156v5              | 0022 | Use of High-Risk<br>Medications in the<br>Elderly<br>Domain: Patient Safety | Percentage of patients 66 years of age and older who were ordered high- risk medications. Two rates are reported.  - Percentage of patients who were ordered at least one high-risk medication.  - Percentage of patients who were ordered at least two different high-risk medications. | Numerator 1: Patients with an order for at least one high-risk medication during the measurement period.  Numerator 2: Patients with an order for at least two different high-risk medications during the measurement period. | Patients 66 years and older who had a visit during the measurement period   | National<br>Committee<br>for Quality<br>Assurance | 238                  |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain  | Measure Description  | Numerator Statement  | Denominator Statement  | Measure<br>Steward                                | PQRS#                      |
|-----------------------|------|--|--|--|--|---|----------------------------|
| CMS155v5              | 0024 | Weight Assessment<br>and Counseling for<br>Nutrition and Physical<br>Activity for Children and<br>Adolescents<br>Domain: Community/<br>Population Health | Percentage of patients 3- 17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.  - Percentage of patients with height, weight, and body mass index (BMI) percentile documentation  - Percentage of patients with counseling for nutrition  - Percentage of patients with counseling for physical activity | Numerator 1: Patients who had a height, weight and body mass index (BMI) percentile recorded during the measurement period Numerator 2: Patients who had counseling for nutrition during a visit that occurs during the measurement period Numerator 3: Patients who had counseling for physical activity during a visit that occurs during the measurement period | Patients 3-17 years of age with at least one outpatient visit with a primary care physician (PCP) or an obstetrician/gynecologist (OB/GYN) during the measurement period | National<br>Committee<br>for Quality<br>Assurance | 239                        |
| CMS138v5              | 0028 | Preventive Care and<br>Screening: Tobacco<br>Use: Screening and<br>Cessation Intervention<br>Domain: Community/<br>Population Health                     | Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user   | Patients who were screened for tobacco use at least once within 24 months AND who received tobacco cessation intervention if identified as a tobacco user  | All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period   | PCPI(R)<br>Foundation<br>(PCPI[R])                | 226<br>GPRO<br>PREV-<br>10 |
| CMS125v5              | 2372 | Breast Cancer<br>Screening<br>Domain: Effective<br>Clinical Care   | Percentage of women 50-<br>74 years of age who had<br>a mammogram to screen<br>for breast cancer   | Women with one or more mammograms during the measurement period or the 15 months prior to the measurement period   | Women 51-74 years of age with a visit during the measurement period  | National<br>Committee<br>for Quality<br>Assurance | 112<br>GPRO<br>PREV-<br>5  |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain   | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward                                | PQRS# |
|-----------------------|------|---|--|---|---|---|-------|
| CMS124v5              | 0032 | Cervical Cancer<br>Screening<br>Domain: Effective<br>Clinical Care          | Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria:  - Women age 21-64 who had cervical cytology performed every 3 years  - Women age 30-64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years | Women with one or more screenings for cervical cancer.  Appropriate screenings are defined by any one of the following criteria:  - Cervical cytology performed during the measurement period or the two years prior to the measurement period for women who are at least 21 years old at the time of the test  - Cervical cytology/human papillomavirus (HPV) co-testing performed during the measurement period or the four years prior to the measurement period for women who are at least 30 years old at the time of the test | Women 23-64 years of age with a visit during the measurement period                               | National<br>Committee<br>for Quality<br>Assurance | 309   |
| CMS153v5              | 0033 | Chlamydia Screening<br>for Women<br>Domain: Community/<br>Population Health | Percentage of women 16-<br>24 years of age who were<br>identified as sexually<br>active and who had at<br>least one test for<br>chlamydia during the<br>measurement period   | Women with at least<br>one chlamydia test<br>during the<br>measurement period   | Women 16 to 24 years of age who are sexually active and who had a visit in the measurement period | National<br>Committee<br>for Quality<br>Assurance | 310   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description   | Numerator Statement   | Denominator Statement   | Measure<br>Steward                                | PQRS#                     |
|-----------------------|-------------------|--|---|---|---|---|---------------------------|
| CMS130v5              | 0034              | Colorectal Cancer<br>Screening<br>Domain: Effective<br>Clinical Care               | Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.  | Patients with one or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the following criteria:  - Fecal occult blood test (FOBT) during the measurement period  - Flexible sigmoidoscopy during the measurement period or the four years prior to the measurement period  - Colonoscopy during the measurement period or the nine years prior to the measurement period or the nine years prior to the measurement period or the nine years prior to the measurement period | Patients 50-75 years of age with a visit during the measurement period                      | National<br>Committee<br>for Quality<br>Assurance | 113<br>GPRO<br>PREV-<br>6 |
| CMS126v5 <sup>a</sup> | Not<br>Applicable | Use of Appropriate<br>Medications for Asthma<br>Domain: Effective<br>Clinical Care | Percentage of patients 5-<br>64 years of age who were<br>identified as having<br>persistent asthma and<br>were appropriately<br>ordered medication during<br>the measurement period | Patients who were ordered at least one prescription for a preferred therapy during the measurement period   | Patients 5-64 years of age with persistent asthma and a visit during the measurement period | National<br>Committee<br>for Quality<br>Assurance | 311                       |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain  | Measure Description  | Numerator Statement   | Denominator Statement  | Measure<br>Steward                                | PQRS#                     |
|-----------------------|------|--|--|---|--|---|---------------------------|
| CMS117v5              | 0038 | Childhood<br>Immunization Status<br>Domain: Community/<br>Population Health                            | Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday | Children who have evidence showing they received recommended vaccines, had documented history of the illness, had a seropositive test result, or had an allergic reaction to the vaccine by their second birthday | Children who turn 2 years of age during the measurement period and who have a visit during the measurement period  | National<br>Committee<br>for Quality<br>Assurance | 240                       |
| CMS147v6              | 0041 | Preventive Care and<br>Screening: Influenza<br>Immunization<br>Domain: Community/<br>Population Health | Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization  | Patients who received<br>an influenza<br>immunization OR who<br>reported previous<br>receipt of an influenza<br>immunization  | All patients aged 6 months and older seen for at least two visits or at least one preventive visit during the measurement period and seen for a visit between October 1 and March 31 | PCPI(R)<br>Foundation<br>(PCPI[R])                | 110<br>GPRO<br>PREV-<br>7 |
| CMS127v5              | 0043 | Pneumococcal Vaccination Status for Older Adults Domain: Community/ Population Health                  | Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine   | Patients who have ever received a pneumococcal vaccination  | Patients 65 years of age<br>and older with a visit<br>during the measurement<br>period   | National<br>Committee<br>for Quality<br>Assurance | 111<br>GPRO<br>PREV-<br>8 |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain   | Measure Description   | Numerator Statement   | Denominator Statement  | Measure<br>Steward                                | PQRS#               |
|-----------------------|------|---|---|---|--|---|---------------------|
| CMS166v6              | 0052 | Use of Imaging Studies<br>for Low Back Pain<br>Domain: Efficiency and<br>Cost Reduction | Percentage of patients 18-<br>50 years of age with a<br>diagnosis of low back pain<br>who did not have an<br>imaging study (plain X-<br>ray, MRI, CT scan) within<br>28 days of the diagnosis.  | Patients without an imaging study conducted on the date of the outpatient or emergency department visit or in the 28 days following the outpatient or emergency department visit  | Patients 18-50 years of age with a diagnosis of low back pain during an outpatient or emergency department visit | National<br>Committee<br>for Quality<br>Assurance | 312                 |
| CMS131v5              | 0055 | Diabetes: Eye Exam<br>Domain: Effective<br>Clinical Care                                | Percentage of patients 18-<br>75 years of age with<br>diabetes who had a retinal<br>or dilated eye exam by an<br>eye care professional<br>during the measurement<br>period or a negative<br>retinal exam (no evidence<br>of retinopathy) in the 12<br>months prior to the<br>measurement period | Patients with an eye screening for diabetic retinal disease. This includes diabetics who had one of the following:  A retinal or dilated eye exam by an eye care professional in the measurement period or a negative retinal exam (no evidence of retinopathy) by an eye care professional in the year prior to the measurement period | Patients 18-75 years of age with diabetes with a visit during the measurement period                             | National<br>Committee<br>for Quality<br>Assurance | 117<br>GPRO<br>DM-7 |
| CMS123v5              | 0056 | Diabetes: Foot Exam<br>Domain: Effective<br>Clinical Care                               | The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a foot exam (visual inspection and sensory exam with mono filament and a pulse exam) during the measurement year   | Patients who received visual, pulse and sensory foot examinations during the measurement period   | Patients 18-75 years of age with diabetes with a visit during the measurement period                             | National<br>Committee<br>for Quality<br>Assurance | 163                 |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain   | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward                                | PQRS#               |
|-----------------------|-------------------|---|--|---|---|---|---------------------|
| CMS122v5              | 0059              | Diabetes: Hemoglobin<br>A1c (HbA1c) Poor<br>Control (> 9%)<br>Domain: Effective<br>Clinical Care            | Percentage of patients 18-<br>75 years of age with<br>diabetes who had<br>hemoglobin A1c > 9.0%<br>during the measurement<br>period                        | Patients whose most recent HbA1c level (performed during the measurement period) is >9.0%                 | Patients 18-75 years of age with diabetes with a visit during the measurement period  | National<br>Committee<br>for Quality<br>Assurance | 001<br>GPRO<br>DM-2 |
| CMS148v5 <sup>a</sup> | Not<br>Applicable | Hemoglobin A1c Test<br>for Pediatric Patients<br>Domain: Effective<br>Clinical Care                         | Percentage of patients 5-<br>17 years of age with<br>diabetes with a<br>Hemoglobin A1c (HbA1c)<br>test during the<br>measurement period                    | Patients with<br>documentation of date<br>and result for a HbA1c<br>test during the<br>measurement period | Patients 5 to 17 years of age with a diagnosis of diabetes where the diagnosis overlaps the most recent visit during the measurement period | National<br>Committee<br>for Quality<br>Assurance | 365                 |
| CMS134v5              | 0062              | Diabetes: Medical<br>Attention for<br>Nephropathy<br>Domain: Effective<br>Clinical Care                     | The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period. | Patients with a screening for nephropathy or evidence of nephropathy during the measurement period        | Patients 18-75 years of age with diabetes with a visit during the measurement period  | National<br>Committee<br>for Quality<br>Assurance | 119                 |
| CMS163v5 <sup>a</sup> | Not<br>Applicable | Diabetes: Low Density<br>Lipoprotein (LDL-C)<br>Control (< 100 mg/dL)<br>Domain: Effective<br>Clinical Care | Percentage of patients 18-<br>75 years of age with<br>diabetes whose LDL-C<br>was adequately controlled<br>(<100 mg/dL) during the<br>measurement period.  | Patients whose most<br>recent LDL-C level<br>performed during the<br>measurement period is<br><100 mg/dL  | Patients 18-75 years of age with diabetes with a visit during the measurement period  | National<br>Committee<br>for Quality<br>Assurance | 002                 |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description  | Numerator Statement  | Denominator Statement  | Measure<br>Steward                                | PQRS#                |
|-----------------------|-------------------|--|--|--|--|---|----------------------|
| CMS164v5              | 0068              | Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet Domain: Effective Clinical Care  | Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antiplatelet during the measurement period. | Patients who had an active medication of aspirin or another antiplatelet during the measurement year                                       | Patients 18 years of age and older with a visit during the measurement period who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD overlapping the measurement year | National<br>Committee<br>for Quality<br>Assurance | 204<br>GPRO<br>IVD-2 |
| CMS154v5              | 0069              | Appropriate Treatment<br>for Children with Upper<br>Respiratory Infection<br>(URI)<br>Domain: Efficiency and<br>Cost Reduction   | Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode   | Children without a prescription for antibiotic medication on or 3 days after the outpatient or ED visit for an upper respiratory infection | Children age 3 months to<br>18 years who had an<br>outpatient or emergency<br>department (ED) visit<br>with a diagnosis of upper<br>respiratory infection<br>(URI) during the<br>measurement period                          | National<br>Committee<br>for Quality<br>Assurance | 065                  |
| CMS145v5              | Not<br>Applicable | Coronary Artery Disease (CAD): Beta- Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) Domain: Effective Clinical Care | Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed betablocker therapy  | Patients who were prescribed beta-blocker therapy  | All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have prior (within the past 3 years) MI or a current or prior LVEF <40%                              | PCPI(R)<br>Foundation<br>(PCPI[R])                | 007                  |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description   | Numerator Statement   | Denominator Statement   | Measure<br>Steward                            | PQRS# |
|-----------------------|-------------------|--|---|---|---|---|-------|
| CMS182v6ª             | Not<br>Applicable | Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (<100 mg/dL) Domain: Effective Clinical Care   | Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose most recent Lowdensity Lipoprotein (LDL-C) was adequately controlled (< 100 mg/dL) | Numerator 1: Patients with a complete lipid profile performed during the measurement period Numerator 2: Patients whose most recent LDL-C level performed during the measurement period is <100 mg/dL | Patients 18 years of age and older with a visit during the measurement year who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD during the measurement year | National<br>Committee<br>Quality<br>Assurance | 241   |
| CMS135v5              | 2907              | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) Domain: Effective Clinical Care | Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge  | Patients who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge   | All patients aged 18 years and older with a diagnosis of heart failure with a current or prior LVEF < 40%   | PCPI(R)<br>Foundation<br>(PCPI[R])            | 005   |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain  | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward                 | PQRS#               |
|-----------------------|------|--|--|---|---|------------------------------------|---------------------|
| CMS144v5              | 2908 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) Domain: Effective Clinical Care                        | Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge       | Patients who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge   | All patients aged 18 years and older with a diagnosis of heart failure with a current or prior LVEF < 40% | PCPI(R)<br>Foundation<br>(PCPI[R]) | 008<br>GPRO<br>HF-6 |
| CMS143v5              | 0086 | Primary Open-Angle<br>Glaucoma (POAG):<br>Optic Nerve Evaluation<br>Domain: Effective<br>Clinical Care   | Percentage of patients aged 18 years and older with a diagnosis of primary open-angle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months  | Patients who have an optic nerve head evaluation during one or more office visits within 12 months  | All patients aged 18 years and older with a diagnosis of primary open-angle glaucoma                      | PCPI(R)<br>Foundation<br>(PCPI[R]) | 012                 |
| CMS167v5              | 0088 | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy Domain: Effective Clinical Care | Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months | Patients who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy AND the presence or absence of macular edema during one or more office visits within 12 months | All patients aged 18 years and older with a diagnosis of diabetic retinopathy                             | PCPI(R)<br>Foundation<br>(PCPI[R]) | 018                 |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain   | Measure Description  | Numerator Statement   | Denominator Statement  | Measure<br>Steward                                | PQRS#                     |
|-----------------------|------|---|--|---|--|---|---------------------------|
| CMS142v5              | 0089 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care Domain: Communication and Care Coordination | Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months | Patients with documentation, at least once within 12 months, of the findings of the dilated macular or fundus exam via communication to the physician who manages the patient's diabetic care | All patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed | PCPI(R)<br>Foundation<br>(PCPI[R])                | 019                       |
| CMS139v5              | 0101 | Falls: Screening for<br>Future Fall Risk<br>Domain: Patient Safety  | Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period  | Patients who were screened for future fall risk at least once within the measurement period   | Patients aged 65 years<br>and older with a visit<br>during the measurement<br>period   | National<br>Committee<br>for Quality<br>Assurance | 318<br>GPRO<br>CARE-<br>2 |
| CMS161v5              | 0104 | Adult Major Depressive<br>Disorder (MDD):<br>Suicide Risk<br>Assessment<br>Domain: Effective<br>Clinical Care                     | Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified  | Patients with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified   | All patients aged 18 years and older with a diagnosis of major depressive disorder (MDD)   | PCPI(R)<br>Foundation<br>(PCPI[R])                | 107                       |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain                                       | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward                                | PQRS# |
|-----------------------|------|---|--|---|---|---|-------|
| CMS128v5              | 0105 | Anti-depressant Medication Management Domain: Effective Clinical Care | Percentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported.  - Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).  - Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks). | Numerator 1: Patients who have received antidepressant medication for at least 84 days (12 weeks) of continuous treatment during the 114-day period following the Index Prescription Start Date Numerator 2: Patients who have received antidepressant medications for at least 180 days (6 months) of continuous treatment during the 231-day period following the Index Prescription Start Date | Patients 18 years of age and older with a visit during the measurement period who were dispensed antidepressant medications in the time within 270 days (9 months) prior to the measurement period through the first 90 days (3 months) of the measurement period, and were diagnosed with major depression 60 days prior to, or 60 days after the dispensing event | National<br>Committee<br>for Quality<br>Assurance | 009   |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and NQS Domain  | Measure Description   | Numerator Statement   | Denominator Statement  | Measure<br>Steward                                | PQRS# |
|-----------------------|------|---|---|---|--|---|-------|
| CMS136v6              | 0108 | ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Domain: Effective Clinical Care | Percentage of children 6- 12 years of age and newly dispensed a medication for attention- deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  - Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  - Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended. | Numerator 1: Patients who had at least one face-to-face visit with a practitioner with prescribing authority within 30 days after the IPSD.  Numerator 2: Patients who had at least one face-to-face visit with a practitioner with prescribing authority during the Initiation Phase, and at least two follow-up visits during the Continuation and Maintenance Phase. One of the two visits during the Continuation and Maintenance Phase may be a telephone visit with a practitioner. | Initial Population 1: Children 6-12 years of age who were dispensed an ADHD medication during the Intake Period and who had a visit during the measurement period. Initial Population 2: Children 6-12 years of age who were dispensed an ADHD medication during the Intake Period and who remained on the medication for at least 210 days out of the 300 days following the IPSD, and who had a visit during the measurement period. | National<br>Committee<br>for Quality<br>Assurance | 366   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain   | Measure Description   | Numerator Statement  | Denominator Statement  | Measure<br>Steward   | PQRS# |
|-----------------------|-------------------|---|---|--|--|--|-------|
| CMS169v5              | Not<br>Applicable | Bipolar Disorder and<br>Major Depression:<br>Appraisal for alcohol or<br>chemical substance<br>use<br>Domain: Effective<br>Clinical Care    | Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use              | Patients in the denominator with evidence of an assessment for alcohol or other substance use following or concurrent with the new diagnosis, and prior to or concurrent with the initiation of treatment for that diagnosis | Patients 18 years of age or older at the start of the measurement period with a new diagnosis of unipolar depression or bipolar disorder during the first 323 days of the measurement period, and evidence of treatment for unipolar depression or bipolar disorder within 42 days of diagnosis. The existence of a 'new diagnosis' is established by the absence of diagnoses and treatments of unipolar depression or bipolar disorder during the 180 days prior to the diagnosis. | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 367   |
| CMS157v5              | 0384              | Oncology: Medical and<br>Radiation – Pain<br>Intensity Quantified<br>Domain: Person and<br>Caregiver-Centered<br>Experience and<br>Outcomes | Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified | Patient visits in which pain intensity is quantified   | All patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy  | PCPI(R)<br>Foundation<br>(PCPI[R])                         | 143   |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain   | Measure Description   | Numerator Statement   | Denominator Statement   | Measure<br>Steward                 | PQRS# |
|-----------------------|------|---|---|---|---|------------------------------------|-------|
| CMS141v6ª             | 0385 | Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients Domain: Effective Clinical Care   | Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period   | Patients who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or who have previously received adjuvant chemotherapy within the 12 month reporting period | All patients aged 18<br>through 80 years with<br>colon cancer with AJCC<br>Stage III colon cancer   | PCPI(R)<br>Foundation<br>(PCPI[R]) | 072   |
| CMS140v5 <sup>a</sup> | 0387 | Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer Domain: Effective Clinical Care | Percentage of female patients aged 18 years and older with Stage I (T1b) through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period   | Patients who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period   | All female patients aged<br>18 years and older with a<br>diagnosis of breast<br>cancer with Stage I (T1b)<br>through IIIC, estrogen<br>receptor (ER) or<br>progesterone receptor<br>(PR) positive breast<br>cancer                                  | PCPI(R)<br>Foundation<br>(PCPI[R]) | 071   |
| CMS129v6              | 0389 | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients Domain: Efficiency and Cost Reduction                        | Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer | Patients who did not have a bone scan performed at any time since diagnosis of prostate cancer  | All patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy | PCPI(R)<br>Foundation<br>(PCPI[R]) | 102   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and NQS Domain  | Measure Description   | Numerator Statement   | Denominator Statement  | Measure<br>Steward                                | PQRS# |
|-----------------------|-------------------|---|---|---|--|---|-------|
| CMS62v5 <sup>a</sup>  | Not<br>Applicable | HIV/AIDS: Medical Visit<br>Domain: Effective<br>Clinical Care                               | Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit | Patients with at least<br>two medical visits<br>during the<br>measurement period<br>with a minimum of 90<br>days between each<br>visit  | All patients, regardless of<br>age, with a diagnosis of<br>HIV/AIDS seen during<br>the measurement period  | National<br>Committee<br>for Quality<br>Assurance | 368   |
| CMS52v5               | 0405              | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis Domain: Effective Clinical Care | Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis                                  | Numerator 1: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis within 3 months of CD4 count below 200 cells/mm3 Numerator 2: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis within 3 months of CD4 count below 500 cells/mm3 or a CD4 percentage below 15% Numerator 3: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis at the time of diagnosis of HIV | Initial Population 1: All patients aged 6 years and older with a diagnosis of HIV/AIDS and a CD4 count below 200 cells/mm3 who had at least two visits during the measurement year, with at least 90 days in between each visit Initial Population 2: All patients aged 1-5 years of age with a diagnosis of HIV/AIDS and a CD4 count below 500 cells/mm3 or a CD4 percentage below 15% who had at least two visits during the measurement year, with at least 90 days in between each visit Initial Population 3: All patients aged 6 weeks to 12 months with a diagnosis of HIV who had at least two visits during the measurement year, with at least 90 days in between each visit | National<br>Committee<br>for Quality<br>Assurance | 160   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description   | Numerator Statement   | Denominator Statement  | Measure<br>Steward   | PQRS#                      |
|-----------------------|-------------------|--|---|---|--|--|----------------------------|
| CMS77v5ª              | Not<br>Applicable | HIV/AIDS: RNA Control<br>for Patients with HIV<br>Domain: Effective<br>Clinical Care   | Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL                        | Patients whose most<br>recent HIV RNA level<br>is <200 copies/mL<br>during the<br>measurement period  | All patients aged 13 years and older with a diagnosis of HIV/AIDS with at least two visits during the measurement year, with at least 90 days between each visit | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 381                        |
| CMS2v6                | 0418              | Preventive Care and<br>Screening: Screening<br>for Depression and<br>Follow-Up Plan<br>Domain: Community/<br>Population Health | Percentage of patients aged 12 years and older screened for depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a followup plan is documented on the date of the positive screen | Patients screened for<br>depression on the date<br>of the encounter using<br>an age appropriate<br>standardized tool AND<br>if positive, a follow-up<br>plan is documented on<br>the date of the positive<br>screen | All patients aged 12 years and older before the beginning of the measurement period with at least one eligible encounter during the measurement period           | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 134<br>GPRO<br>PREV-<br>12 |

| CMS<br>eMeasure<br>ID | NQF# | Measure Title and<br>NQS Domain   | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward   | PQRS#                     |
|-----------------------|------|---|--|---|---|--|---------------------------|
| CMS68v6               | 0419 | Documentation of<br>Current Medications in<br>the Medical Record<br>Domain: Patient Safety  | Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, overthe-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration. | Eligible professional attests to documenting, updating or reviewing the patient's current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosages, frequency and route of administration | All visits occurring during the 12 month reporting period for patients aged 18 years and older before the start of the measurement period | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 130<br>GPRO<br>CARE-<br>3 |
| CMS69v5               | 0421 | Preventive Care and<br>Screening: Body Mass<br>Index (BMI) Screening<br>and Follow-Up Plan<br>Domain: Community/<br>Population Health | Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter  Normal Parameters:  Age 18 years and older  BMI => 18.5 and < 25 kg/m2  | Patients with a documented BMI during the encounter or during the previous six months, AND when the BMI is outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter   | All patients 18 and older on the date of the encounter with at least one eligible encounter during the measurement period                 | Centers for<br>Medicare &<br>Medicaid<br>Services          | 128<br>GPRO<br>PREV-<br>9 |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward                 | PQRS# |
|-----------------------|-------------------|--|--|---|---|------------------------------------|-------|
| CMS132v5              | 0564              | Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures Domain: Patient Safety   | Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence | Patients who had one or more specified operative procedures for any of the following major complications within 30 days following cataract surgery: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence | All patients aged 18 years and older who had cataract surgery and no significant ocular conditions impacting the surgical complication rate | PCPI(R)<br>Foundation<br>(PCPI[R]) | 192   |
| CMS133v5              | 0565              | Cataracts: 20/40 or<br>Better Visual Acuity<br>within 90 Days<br>Following Cataract<br>Surgery<br>Domain: Effective<br>Clinical Care | Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery  | Patients who had best-<br>corrected visual acuity<br>of 20/40 or better<br>(distance or near)<br>achieved within 90<br>days following cataract<br>surgery   | All patients aged 18 years and older who had cataract surgery   | PCPI(R)<br>Foundation<br>(PCPI[R]) | 191   |
| CMS158v5              | Not<br>Applicable | Pregnant women that<br>had HBsAg testing<br>Domain: Effective<br>Clinical Care   | This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy   | Patients who were<br>tested for hepatitis B<br>surface antigen<br>(HBsAg) during<br>pregnancy within 280<br>days prior to delivery  | All female patients aged<br>12 and older who had a<br>live birth or delivery<br>during the measurement<br>period                            | Optum                              | 369   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain   | Measure Description  | Numerator Statement   | Denominator Statement   | Measure<br>Steward   | PQRS#               |
|-----------------------|-------------------|---|--|---|---|--|---------------------|
| CMS159v5              | 0710              | Depression Remission<br>at Twelve Months<br>Domain: Effective<br>Clinical Care                                      | Patients age 18 and older with major depression or dysthymia and an initial Patient Health Questionnaire (PHQ-9) score greater than nine who demonstrate remission at twelve months (+/- 30 days after an index visit) defined as a PHQ-9 score less than five. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment. | Patients who achieved remission at twelve months as demonstrated by a twelve month (+/- 30 days grace period) PHQ-9 score of less than five | Patients age 18 and older with a diagnosis of major depression or dysthymia and an initial PHQ-9 score greater than nine during the index visit | MN<br>Community<br>Measurement                             | 370<br>GPRO<br>MH-1 |
| CMS160v5              | 0712              | Depression Utilization<br>of the PHQ-9 Tool<br>Domain: Effective<br>Clinical Care                                   | Patients age 18 and older with the diagnosis of major depression or dysthymia who have a Patient Health Questionnaire (PHQ-9) tool administered at least once during a 4-month period in which there was a qualifying visit  | Patients who have a<br>PHQ-9 tool<br>administered at least<br>once during the four-<br>month period   | Patients age 18 and older with an office visit and the diagnosis of major depression or dysthymia during the four month period                  | MN<br>Community<br>Measurement                             | 371                 |
| CMS75v5               | Not<br>Applicable | Children Who Have Dental Decay or Cavities Domain: Community/ Population Health                                     | Percentage of children,<br>age 0-20 years, who have<br>had tooth decay or<br>cavities during the<br>measurement period   | Children who had cavities or decayed teeth  | Children, age 0-20 years, with a visit during the measurement period  | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 378                 |
| CMS177v5              | 1365              | Child and Adolescent<br>Major Depressive<br>Disorder (MDD):<br>Suicide Risk<br>Assessment<br>Domain: Patient Safety | Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk  | Patient visits with an assessment for suicide risk  | All patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder                                     | PCPI(R)<br>Foundation<br>(PCPI[R])                         | 382                 |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain   | Measure Description   | Numerator Statement  | Denominator Statement   | Measure<br>Steward   | PQRS# |
|-----------------------|-------------------|---|---|--|---|--|-------|
| CMS82v4               | Not<br>Applicable | Maternal Depression<br>Screening<br>Domain: Community/<br>Population Health   | The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during child's first 6 months, and who had a maternal depression screening for the mother at least once between 0 and 6 months of life. | Children with documentation of maternal screening or treatment for postpartum depression for the mother. | Children with a visit who turned 6 months of age in the measurement period. | National<br>Committee<br>for Quality<br>Assurance          | 372   |
| CMS74v6               | Not<br>Applicable | Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists Domain: Effective Clinical Care | Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.  | Children who receive a fluoride varnish application  | Children, age 0-20 years, with a visit during the measurement period        | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 379   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and NQS Domain  | Measure Description  | Numerator Statement   | Denominator Statement  | Measure<br>Steward   | PQRS# |
|-----------------------|-------------------|---|--|---|--|--|-------|
| CMS61v6ª              | Not<br>Applicable | Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed Domain: Effective Clinical Care | Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed. | Numerator 1: (High Risk) Patients who had a fasting LDL-C test performed or a calculated LDL-C during the measurement period Numerator 2: (Moderate Risk) Patients who had a fasting LDL-C test performed or a calculated LDL-C during the measurement period Numerator 3: (Low Risk) Patients who had a fasting LDL-C test performed or a calculated LDL-C during the measurement period or up to four (4) years prior to the current measurement period | Denominator 1: (High Risk) All patients aged 20 through 79 years who have CHD or CHD Risk Equivalent OR 10-Year Framingham Risk > 20% Denominator 2: (Moderate Risk) All patients aged 20 through 79 years who have 2 or more Major CHD Risk Factors OR 10-Year Framingham Risk 10-20% Denominator 3: (Low Risk) All patients aged 20 through 79 years who have 0 or 1 Major CHD Risk Factors OR 10-Year Framingham Risk <10% ** For Denominator 2 and Denominator 3, Fasting HDL-C > or equal to 60 mg/dL subtracts 1 risk from the above (This is a negative risk factor.) | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 316   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description   | Numerator Statement  | Denominator Statement  | Measure<br>Steward   | PQRS# |
|-----------------------|-------------------|--|---|--|--|--|-------|
| CMS64v6ª              | Not<br>Applicable | Preventive Care and Screening: Risk-Stratified Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Domain: Effective Clinical Care | Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose risk-stratified fasting LDL-C is at or below the recommended LDL-C goal. | Numerator 1:Patients whose most recent fasting LDL-C test result is in good control, defined as <100 mg/dL Numerator 2:Patients whose most recent fasting LDL-C test result is in good control, defined as <130 mg/dL Numerator 3:Patients whose most recent fasting LDL-C test result is in good control, defined as <160 mg/dL | Denominator 1: (High Risk) All patients aged 20 through 79 years who had a fasting LDL-C or a calculated LDL-C test performed during the measurement period and have CHD or CHD Risk Equivalent OR 10 year Framingham risk > 20%. Denominator 2: (Moderate Risk) All patients aged 20 through 79 years who had a fasting LDL-C or a calculated LDL-C test performed during the measurement period and have 2 or more Major CHD Risk Factors OR 10 year Framingham Risk 10-20%. Denominator 3: (Low Risk) All patients aged 20 through 79 years who had a fasting LDL-C or a calculated LDL-C test performed up to 4 years prior to the current measurement period and have 0 or 1 Major CHD Risk Factors OR 10 year Framingham risk <10%.  **For Denominator 2 and Denominator 3, HDL-C > or equal to 60 mg/dL subtracts 1 risk from the above (This is a negative risk factor.) | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 316   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description  | Numerator Statement  | Denominator Statement  | Measure<br>Steward   | PQRS# |
|-----------------------|-------------------|--|--|--|--|--|-------|
| CMS149v5              | Not<br>Applicable | Dementia: Cognitive<br>Assessment<br>Domain: Effective<br>Clinical Care  | Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12 month period | Patients for whom an assessment of cognition is performed and the results reviewed at least once within a 12 month period  | All patients, regardless of age, with a diagnosis of dementia  | PCPI(R)<br>Foundation<br>(PCPI[R])                         | 281   |
| CMS65v6               | Not<br>Applicable | Hypertension:<br>Improvement in Blood<br>Pressure<br>Domain: Effective<br>Clinical Care                            | Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.   | Patients whose follow-<br>up blood pressure is at<br>least 10 mmHg less<br>than their baseline<br>blood pressure or is<br>adequately controlled.<br>If a follow-up blood<br>pressure reading is not<br>recorded during the<br>measurement year, the<br>patient's blood<br>pressure is assumed<br>"not improved." | All patients aged 18-85 years of age, who had at least one outpatient visit in the first six months of the measurement year, who have a diagnosis of essential hypertension documented during that outpatient visit, and who have uncontrolled baseline blood pressure at the time of that visit | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 373   |
| CMS50v5               | Not<br>Applicable | Closing the Referral<br>Loop: Receipt of<br>Specialist Report<br>Domain:<br>Communication and<br>Care Coordination | Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred                          | Number of patients with a referral, for which the referring provider received a report from the provider to whom the patient was referred  | Number of patients, regardless of age, who were referred by one provider to another provider, and who had a visit during the measurement period  | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 374   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain   | Measure Description   | Numerator Statement   | Denominator Statement  | Measure<br>Steward   | PQRS# |
|-----------------------|-------------------|---|---|---|--|--|-------|
| CMS66v5               | Not<br>Applicable | Functional Status Assessment for Total Knee Replacement Domain: Person and Caregiver-Centered Experience and Outcomes | Percentage of patients 18 years of age and older with primary total knee arthroplasty (TKA) who completed baseline and follow-up patient-reported functional status assessments | Patients with patient-reported functional status assessment results (eg, VR-12, VR-36, PROMIS-10 Global Health, PROMIS-29, KOOS) not more than 180 days prior to the primary TKA procedure, and at least 60 days and not more than 180 days after TKA procedure | Patients 18 years of age and older who had a primary total knee arthroplasty (TKA) within the 12 month period that begins 180 days before the start of the measurement period and ends 185 days after the start of the measurement period and who had an outpatient encounter not more than 180 days prior to procedure, and at least 60 days and not more than 180 days after TKA procedure | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 375   |
| CMS56v5               | Not<br>Applicable | Functional Status Assessment for Total Hip Replacement Domain: Person and Caregiver-Centered Experience and Outcomes  | Percentage of patients 18 years of age and older with primary total hip arthroplasty (THA) who completed baseline and follow-up patient-reported functional status assessments  | Patients with patient-reported functional status assessment results (eg, VR-12, VR-36, PROMIS-10-Global Health, PROMIS-29, HOOS) not more than 180 days prior to the primary THA procedure, and at least 60 days and not more than 180 days after THA procedure | Patients 18 years of age and older who had a primary total hip arthroplasty (THA) within the 12 month period that begins 180 days before the start of the measurement period and ends 185 days after the start of the measurement period and who had an outpatient encounter not more than 180 days prior to procedure, and at least 60 days and not more than 180 days after THA procedure  | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 376   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and NQS Domain   | Measure Description  | Numerator Statement   | Denominator Statement  | Measure<br>Steward   | PQRS# |
|-----------------------|-------------------|--|--|---|--|--|-------|
| CMS90v6               | Not<br>Applicable | Functional Status Assessments for Congestive Heart Failure Domain: Person and Caregiver-Centered Experience and Outcomes | Percentage of patients 65 years of age and older with congestive heart failure who completed initial and follow-up patient-reported functional status assessments  | Patients with patient reported functional status assessment results (eg, VR-12; VR-36; MLHF-Q; KCCQ; PROMIS-10 Global Health, PROMIS-29) present in the EHR within two weeks before or during the initial encounter and the follow-up encounter during the measurement year | Patients 65 years of age and older who had two outpatient encounters during the measurement year and a diagnosis of congestive heart failure   | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 377   |
| CMS179v5 <sup>a</sup> | Not<br>Applicable | ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range Domain: Patient Safety                                 | Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period. | Measure Observations Statement: Average percentage of time that patients in the measure population have INR results within the therapeutic range (i.e., TTR)  | Initial Population Statement: Patients aged 18 and older with atrial fibrillation without valvular heart disease who had been on chronic warfarin therapy for at least 180 days before the start of and during the measurement period. Patient should have at least one outpatient visit during the measurement period Measure Population Statement: Equals all in Initial Population with sufficient international normalized ratio (INR) results to calculate a warfarin time in therapeutic range (TTR) | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 380   |

| CMS<br>eMeasure<br>ID | NQF#              | Measure Title and<br>NQS Domain  | Measure Description  | Numerator Statement  | Denominator Statement  | Measure<br>Steward   | PQRS#                      |
|-----------------------|-------------------|--|--|--|--|--|----------------------------|
| CMS22v5               | Not<br>Applicable | Preventive Care and<br>Screening: Screening<br>for High Blood Pressure<br>and Follow-Up<br>Documented<br>Domain: Community/<br>Population Health | Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated | Patients who were screened for high blood pressure AND have a recommended follow-up plan documented, as indicated if the blood pressure is prehypertensive or hypertensive | All patients aged 18 years and older before the start of the measurement period with at least one eligible encounter during the measurement period | Centers for<br>Medicare &<br>Medicaid<br>Services<br>(CMS) | 317<br>GPRO<br>PREV-<br>11 |

<sup>&</sup>lt;sup>a</sup> eCQM removed for Eligible Clinician reporting for the 2017 MIPS performance period.